Dyslipidemia Management

My Settings
Relevant Content
Bile Acids, Mitochondria, and Myocardial Stiffness: A Shared Mechanism in Fontan Circulation and Metabolic Dysfunction-Associated Steatotic Liver Disease
Circulation: Heart Failure, Ahead of Print.
Is Placebo Still Ethical in Trials of Incretin Therapies?
Circulation, Volume 153, Issue 14, Page 1005-1008, April 7, 2026.
Cardiovascular–Kidney–Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study
Circulation, Ahead of Print.
BACKGROUND:Suboptimal cardiovascular–kid...
Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit
Circulation: Heart Failure, Ahead of Print.
Heart failure with preser...
Lipoprotein(a): An Atherosclerotic Cardiovascular Disease Risk Factor That Can No Longer Be Ignored
2026 Guideline on the Management of Dyslipidemia
This guideline retires and replaces the 2018 AHA/ACC Guideline on the Mana...
Lp(a) in Focus: Breakthrough Therapies and Clinical Implications
Screening Diagnosis and Management of Pediatric Hypertriglyceridemia
Pediatric hypertriglyceridemia is increasingly prevalent, affecting up to...
Cellular Interactions and Immunometabolic Mechanisms in Heart Failure With Preserved Ejection Fraction: From Molecular Mechanisms to Clinical Evidence
Circulation: Heart Failure, Ahead of Print.
Heart failure with preser...
2026 Heart Disease and Stroke Statistics
AHA and NIH’s 2026 Statistics Update delivers the latest U.S. data on hear...